Related Experiment Video

Updated: Apr 25, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.3K

Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities (review)

Paul Toren1, Amina Zoubeidi1

  • 1The Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia V6H 3Z6, Canada.

International Journal of Oncology
|August 15, 2014
PubMed

Insights

Targeting the PI3K/Akt pathway is crucial for aggressive prostate cancer. This review covers pre-clinical and clinical data on targeting this pathway, including combination therapies, to improve patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • The Phosphatidylinositol 3-kinase/Akt (PI3K/Akt) pathway is frequently activated in aggressive prostate cancers.
  • Pathway activation correlates with disease progression, metastasis, and resistance.
  • Biomarkers indicate PI3K/Akt pathway activation in high-grade and progressive prostate cancer.

Purpose of the Study:

  • To review pre-clinical and clinical data on targeting the PI3K/Akt pathway in prostate cancer.
  • To discuss the rationale and relevance of co-targeting strategies.
  • To highlight the importance of biomarkers and combination therapies for optimizing treatment.

Main Methods:

  • Review of pre-clinical studies investigating PI3K/Akt pathway inhibitors.
  • Analysis of clinical trial data for PI3K/Akt pathway-targeted therapies.
  • Evaluation of biomarker studies associated with PI3K/Akt pathway activation.

Main Results:

  • PI3K/Akt pathway signaling drives survival, growth, metabolism, and metastasis in aggressive cancers.
  • Pre-clinical and clinical data support targeting the PI3K/Akt pathway in prostate cancer.
  • Co-targeting approaches show promise for overcoming resistance mechanisms.

Conclusions:

  • Targeting the PI3K/Akt pathway is a key strategy for treating aggressive prostate cancer.
  • Understanding pathway biology and utilizing biomarkers can guide effective combination therapies.
  • Optimized targeting strategies are expected to improve outcomes for patients with advanced disease.

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.3K
Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

8.3K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.6K
IP3/DAG Signaling Pathway01:11

IP3/DAG Signaling Pathway

Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the  phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and...
12.4K